Mizuho Securities analyst Difei Yang maintained a Buy rating on Selecta Biosciences (NASDAQ: SELB) today and set a price target of $30. The company’s shares closed yesterday at $13.02. Yang wrote: “We do not see quarterly earnings as the most

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zogenix (NASDAQ:ZGNX), Spark Therapeutics (NASDAQ:ONCE) and Arqule (NASDAQ:ARQL). Zogenix (ZGNX) Mizuho Securities analyst Difei Yang maintained a Buy rating on Zogenix today and set a

Mizuho Securities analyst Difei Yang maintained a Buy rating on Spark Therapeutics (NASDAQ: ONCE) today. The company’s shares closed yesterday at $56.01. Yang wrote: “We further think it is pre-mature to draw the conclusion that SPK-8011 is inferior to the

In a report released today, Difei Yang from Mizuho Securities upgraded Audentes Therapeutics (NASDAQ: BOLD) to Buy, with a price target of $45. The company’s shares closed yesterday at $34.25. Yang wrote: “We do not see quarterly earnings as the